HomeCannabisNuCana to Participate in Citi's 17th Annual BioPharma Conference

NuCana to Participate in Citi’s 17th Annual BioPharma Conference

Published on

EDINBURGH, United Kingdom, Aug. 31, 2022 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) announced today that management will host one-on-one meetings at Citi’s 17th Annual BioPharma Conference.

Event: Citi’s 17th Annual BioPharma Conference

Dates: September 6-8, 2022

Location: Boston, MA


About NuCana


NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, they have significant shortcomings that limit their efficacy and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome the key limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s pipeline includes NUC-3373 and NUC-7738. NUC-3373 is a new chemical entity derived from the nucleoside analog 5-fluorouracil, a widely used chemotherapy agent. NUC-3373, in combination with other agents, is in a Phase 1b/2 study in patients with metastatic colorectal cancer. NuCana has also initiated a randomized Phase 2 study of NUC-3373, in combination with other agents, for the second-line treatment of patients with advanced colorectal cancer. In addition, NuCana has initiated a Phase 1b/2 modular study of NUC-3373 in combination with other agents, including a PD-1 inhibitor, in patients with advanced solid tumors to identify additional indications for development. NUC-7738 is a transformation of 3’-deoxyadenosine, a novel anti-cancer nucleoside analog. NUC-7738 is in the Phase 2 part of a Phase 1/2 study in patients with advanced solid tumors which is evaluating NUC-7738 as a monotherapy and in combination with a PD-1 inhibitor.


Forward-Looking Statements



This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company’s goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) on April 27, 2022, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

For more information, please contact:

NuCana plc

Hugh S. Griffith

Chief Executive Officer

+44 131 357 1111


[email protected]

ICR Westwicke

Chris Brinzey

+1 339-970-2843


[email protected]

RooneyPartners

Marion Janic

+1 212-223-4017


[email protected]

ti?nf=ODYzNzYwNyM1MTI3NzE2IzIwOTEyOTE= NuCana to Participate in Citi's 17th Annual BioPharma Conference

Featured image: Megapixl © CannabisPic

Disclaimer

Latest News

CNBX Peer-reviewed Study: “Possible Future Therapeutic Value” for CNBX Proprietary Drug Candidate

CNBX Peer-reviewed Study: "Possible Future Therapeutic Value" for...

Heritage Cannabis Announces Second Amendment to Senior Secured Loan and a Facility Increase to $19.775 Million

Toronto, ON, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Heritage...

Grown Rogue Reports Third Quarter 2022 Results, Positive Free Cash Flow and Net Income

Grown Rogue Reports Third Quarter 2022 Results, Positive...

FIRST-EVER TOM’S OF MAINE INCUBATOR TO ELEVATE NEXT GENERATION OF BIPOC ENVIRONMENTAL LEADERS

FIRST-EVER TOM'S OF MAINE INCUBATOR TO ELEVATE NEXT...

More like this

Canopy Growth Announces Divestiture of Canadian Retail Operations

Canopy Growth Announces Divestiture of Canadian Retail Operations ...

CV Sciences, Inc. Announces Proposed Settlement of Shareholder Litigation

CV Sciences, Inc. Announces Proposed Settlement of Shareholder...

ePlus Achieves Palo Alto Networks Authorized Support Center Certified Partner Status

ePlus Achieves Palo Alto Networks Authorized Support Center...

SweetWater Brewing Company Unveils New Fall Craft-Beer Releases

SweetWater Launches New IPA Variety 12-Pack, Introduces New H.A.Z.Y Double IPA and Brings Back...

Cannabis companies are thriving as a result of Europe’s call for medical marijuana

A South African manufacturer has sold all of its output for the upcoming year...